News ReleasesRSS
- Mar 14, 2024 Chugai Files New Drug Application in Japan for Mosunetuzumab for Relapsed or Refractory Follicular Lymphoma
- Mar 14, 2024 Chugai Files for Additional Indication of Tecentriq for the Treatment of Alveolar Soft Part Sarcoma, an Ultra-rare Disease
- Mar 11, 2024 Chugai Selected as “Health & Productivity Stock” for the First Time
- Mar 11, 2024 Galderma Announces Nemolizumab Data at American Academy of Dermatology (AAD) Annual Meeting
- Feb 29, 2024 Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Selpercatinib for RET Fusion-Positive Solid Tumors
What's NewRSS
- Feb 27, 2024 Notice of Convocation of the AGM of Shareholders for the Business Term ended December 31, 2023
- Feb 01, 2024 Conference on FY 2023.12 Financial Results
- Feb 01, 2024 Financial Results for the Fiscal Year ended December 2023
- Dec 12, 2023 Chugai R&D Meeting
- Dec 06, 2023 The dates of the Financial Results for 2023 FY, 2024 Q1, Q2, and Q3 have been updated.